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Abstract
CRISPR/Cas9 has emerged as a revolutionary tool for fast and efficient targeted gene knockouts 
and genome editing in almost any organism. The laboratory model tunicate Ciona is no exception. 
Here we describe our latest protocol for the design, implementation, and evaluation of successful 
CRISPR/Cas9-mediated gene knockouts in somatic cells of electroporated Ciona embryos. Using 
commercially available reagents, publically accessible plasmids, and free web-based software 
applications, any Ciona researcher can easily knock out any gene of interest in their favorite 
embryonic cell lineage.
Developmental biologists have always been interested in targeted loss-of-function mutations 
to probe the role of specific genes in embryogenesis and regeneration. One approach towards 
this goal has been to engineer the sequence-specificity of DNA-binding domains found in 
natural transcription factors. When these customized DNA-binding proteins are fused to 
DNA nuclease domains, they are capable of inducing site-specific double-stranded breaks 
(DSBs), resulting in mutations through improper repair of these breaks by non-homologous 
end joining (NHEJ). Among these engineered reagents are the Zinc Finger Nucleases 
(ZFNs)(BEERLI AND BARBAS 2002; BIBIKOVA et al. 2003; MAEDER et al. 2008) and Transcription 
Activator-Like Effector Nucleases (TALENs)(CHRISTIAN et al. 2010; MILLER et al. 2011). Both 
ZFNs and TALENs have been used for targeted mutagenesis in Ciona embryos (KAWAI et al. 
2012; TREEN et al. 2014; YOSHIDA et al. 2014).
While these programmable nucleases made it possible to cause site-directed DSBs at any 
part of the genome, even in a tissue- or cell lineage-specific manner, expensive and tedious 
cloning procedures posed as a barrier to their widespread adoption and hampered their 
scaling for higher-throughput applications such as genome-wide reverse genetic screens. 
More recently, a targeted platform known as Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)/Cas9 was developed, based on the immune response 
mechanism of Streptococcus bacteria (BARRANGOU et al. 2007; JINEK et al. 2012; CONG et al. 
2013; JINEK et al. 2013; MALI et al. 2013). In these bacteria, processed short CRISPR RNA 
sequences guide the Cas9 protein to specific target sites on foreign DNA. Cas9 is 
characterized by two signature nuclease domains, and interacts with a DNA sequence 
(‘NGG’ for S. pyogenes Cas9) known as the Protospacer Adjacent Motif (PAM). Sequence-
specific base-pairing between the Cas9-associated short RNAs and protospacer DNA 
*Authors for correspondence: lc121@nyu.edu (L.C.), stolfidobranchia@gmail.com (A.S).
#Present address: Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA
HHS Public Access
Author manuscript
Adv Exp Med Biol. Author manuscript; available in PMC 2018 July 26.
Published in final edited form as:
Adv Exp Med Biol. 2018 ; 1029: 141–152. doi:10.1007/978-981-10-7545-2_13.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
sequence of 20 bp adjacent to the PAM then triggers the protein’s nuclease activity, resulting 
in cleavage of both strands of the target sequence (GARNEAU et al. 2010; DELTCHEVA et al. 
2011; GASIUNAS et al. 2012; ANDERS et al. 2014; JINEK et al. 2014).
In its native context, two distinct short RNAs guide Cas9: CRISPR RNA (crRNA) and trans-
activating crRNA (tracrRNA). However, a chimeric “single-guide RNA” (sgRNA) is 
sufficient to mimic the roles of these two components (JINEK et al. 2012). This small but 
profound improvement has helped launch CRISPR/Cas9 as a cheap, simple, and efficient 
system for targeted mutagenesis in a remarkably wide variety of organisms (PERRY AND HENRY 
2015; IAFFALDANO et al. 2016; LONG et al. 2016; NOMURA et al. 2016; NYMARK et al. 2016; TIAN 
et al. 2016), as well as in tunicates (SASAKI et al. 2014; STOLFI et al. 2014; ABDUL-WAJID et al. 
2015; COTA AND DAVIDSON 2015; GANDHI et al. 2016; SEGADE et al. 2016; TOLKIN AND CHRISTIAEN 
2016).
Modifications to the CRISPR/Cas9 system have allowed for further applications, such as 
targeted knock-ins (WANG et al. 2013), transcriptional activation or repression (MAEDER et al. 
2013; PEREZ-PINERA et al. 2013; QI et al. 2013), chromatin modifications (HILTON et al. 2015), 
and the visualization of genome organization and dynamics (CHEN et al. 2013), although 
these approaches have yet to be adapted to tunicates. Similarly, other CRISPR variants such 
as CRISPR/Cpf1 have been developed for targeted mutagenesis in mammalians (KLEINSTIVER 
et al. 2015; ZETSCHE et al. 2015), but their effects have not yet been tested in Ciona.
In Ciona, the most widely used application of CRISPR to date is for targeted mutagenesis in 
somatic cells of transiently-transfected (electroporated) embryos. In this method, in vitro-
fertilized embryos are electroporated at the one-cell stage with plasmids that drive the 
zygotic expression of Cas9 protein and sgRNAs. While sgRNAs are transcribed ubiquitously 
from a U6 small RNA promoter (NISHIYAMA AND FUJIWARA 2008), by RNA polymerase III 
(RNAPolIII), Cas9 can be expressed in a cell-specific manner by using a lineage-specific 
promoter. We use a humanized Cas9 flanked by nuclear localization signals 
(NLS::Cas9::NLS)(CHEN et al. 2013; STOLFI et al. 2014), though other Cas9 variants have not 
been thoroughly evaluated in Ciona. Targeted mutations will occur only when both Cas9 and 
the sgRNA are present, and can happen on different sister chromatids in different cells at 
different times. This means that each embryo is actually a mosaic composed of cells bearing 
a combination of wildtype and/or distinct mutant alleles. In spite of this mosaicism, somatic 
knockouts are a powerful means to dissect the tissue-specific functions of a gene in 
development.
Here we present our latest protocols for generating successful CRISPR/Cas9-mediated 
mutagenesis (hereinafter referred to as “CRISPR knockouts”) in somatic cells of Ciona 
embryos, based on our published and unpublished reports (STOLFI et al. 2014; GANDHI et al. 
2016). The aim of this chapter is to empower laboratories working on Ciona (and other 
tunicates) to harness the power of this simple but very effective tool. The protocols presented 
here only use widely available commercial reagents, and all plasmids can be ordered from 
Addgene (https://www.addgene.org/Lionel_Christiaen/).
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sgRNA design
Perhaps nothing is more important for successful CRISPR knockouts in Ciona than selecting 
the right sgRNAs, which vary widely in their ability to actually induce Cas9-mediated 
DSBs. We refer to this as sgRNA mutagenesis “activity” or, more precisely, efficacy. Some 
sgRNAs will be highly active, while others may not yield detectable mutations. Predicting 
which sgRNAs will cause either frequent or rare mutations is a arduous and potentially 
frustrating task. Many high-throughput studies have sought to create predictive algorithms to 
distinguish, a priori, “good” vs. “bad” sgRNAs. A recent meta-study of these methods 
(HAEUSSLER et al. 2016) concluded that most available algorithms do not accurately predict 
the activity of sgRNAs outside a narrow range of organisms, cell types, or experimental 
conditions. The authors recommended two such algorithms, depending on the method of 
sgRNA transcription (in vivo by RNA polymerase III, or in vitro by viral T7 RNA 
polymerase). This is because the efficacy of an sgRNA is probably contingent upon its 
expression level and stability, which will vary depending on the methods used to transcribe 
it. According to their comparisons, Fusi/Doench is the more accurate predictive algorithm 
for in vivo-transcribed sgRNAs in metazoans including Ciona (FUSI et al. 2015; DOENCH et al. 
2016), while CRISPRScan (MORENO-MATEOS et al. 2015) is recommended for predicting the 
activity of T7-transcribed sgRNAs.
The CRISPOR portal incorporates these findings and features into a useful web-based 
CRISPR sgRNA design tool (http://crispor.tefor.net/)(HAEUSSLER et al. 2016). The input is 
any sequence from the Ciona genome (three different assembly versions are supported), and 
the output is every valid sgRNA target, their scores by the various algorithms used to predict 
efficacy and specificity, and primer sequences for constructing an expression vector.
Important considerations for sgRNA design and selection include not only predicted cutting 
efficiency, but also off-target effects and possible escape by polymorphisms in the target 
sequence. Ideally, an sgRNA should match extensively only one site in the genome (the 
target site) and no other site, which could be potentially cleaved as a result. On the other 
hand, single nucleotide polymorphisms (SNPs) and other naturally occurring mutations can 
prevent sgRNA pairing to the intended target, precluding efficient cleavage by Cas9. While 
the compact genome of Ciona depresses off-target effects, SNPs are extremely frequent in 
genetically diverse wild Ciona populations (SATOU et al. 2012). CRISPOR v4.0 takes both 
off-targets and SNPs into account. Individual SNPs and sites of potential off-target effect are 
shown for each candidate sgRNA, which allows the user to choose whether the sgRNA is 
worth using or not.
Considerable attention must also be paid to selecting the location of the sgRNA target within 
a locus of interest. Our analysis of CRISPR/Cas9 knockouts in Ciona indicates that, as in 
other organisms, NHEJ repair of targets cleaved by Cas9 overwhelmingly favors short indels 
(GANDHI et al. 2016). If targeting coding sequence, there is a 2-in-3 chance that the indel will 
result in a frameshift, and likely premature stop codon. Conversely, there is a 1-in-3 chance 
that an in-frame indel will be generated, which may or may not affect the function of the 
resulting protein. Bear in mind that, once an indel is generated, the sgRNA will no longer 
match to the target site. This means that CRISPR/Cas9-generated mutations are all-or-
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nothing and irreversible. If deleting a few amino acid residues from the target region does 
not affect the function of your protein of interest, then 1/3 of the alleles in your embryo will 
be virtually wild-type, even assuming a 100% mutagenesis rate.
While a short out-of-frame indel can result in a loss-of-function allele, in certain cases the 
truncated protein may act as a neomorphic variant, like a “dominant-negative”. The further 
the target is from the translation start site, the higher the chance that a CRISPR/Cas9-
generated indel will result in a truncated protein. However, if the indel is too close to the 
translation start, translation initiation may simply shift to a downstream start codon, with 
little impact on resulting protein function. Thus, selecting a good sgRNA also depends on 
finding this “sweet spot”, which will vary from protein to protein.
An effective strategy to circumvent all these potential pitfalls is to use two or more highly 
active sgRNAs in combination. This increases the odds of generating at least one out-of-
frame indel, and the large deletions spanning multiple targets have been consistently 
observed in Ciona embryos (GANDHI et al. 2016), the largest deletion reported being ~13 kb 
(ABDUL-WAJID et al. 2015).
sgRNA expression cassette construction by One-step Overlap PCR (OSO-
PCR)
CRISPOR will return a list of sgRNA targets and their relevant efficacy and specificity 
scores and information. A link is provided for each target to a page that lists the 
oligonucleotide sequences one needs to order to construct the sgRNA expression vector 
according to a variety of strategies. For Ciona, the relevant primers are for One-Step Overlap 
PCR (OSO-PCR)(URBAN et al. 1997), which allows for the rapid synthesis of a U6>sgRNA 
cassette in a single PCR reaction (GANDHI et al. 2016). The target-specific sequence (the 
“protospacer”) of any sgRNA cassette is only 19 bp. Thus, in OSO-PCR, limiting amounts 
of unique overlap primers generate a protospacer “bridge” between universal U6 promoter 
and sgRNA scaffold sequences, which are amplified from separate template molecules. In 
Ciona, a modified sgRNAF+E scaffold is used to increase stability and decrease premature 
termination of transcription (ORIOLI et al. 2011; CHEN et al. 2013; STOLFI et al. 2014).
sgRNA expression cassettes can then be electroporated directly into Ciona embryos as 
unpurified PCR products for in vivo transcription, or further processed/purified for cloning 
into plasmid for long-term storage/propagation. We can reliably detect mutagenesis activity 
of sgRNAs transcribed in embryos electroporated with as little as 20 μl of unpurified OSO-
PCR reaction per 700 μl electroporation volume (see Peakshift assay, below). This makes it 
possible to test a large number of candidate sgRNAs quickly.
Step-by-step protocol (adapted from Gandhi et al. 2016):
1- If selecting target using CRISPOR, select those with high Fusi/Doench scores (>60) and 
no known SNPs or off-targets. Click on “PCR primers” link underneath the target sequence 
and you will find the pre-designed primers for OSO-PCR ready to be ordered from your 
preferred oligonucleotide vendor. With oligos in hand, skip ahead to step 5.
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If you have to identify targets and design primers manually, look for candidate targets of 
N(19) + PAM (“NGG”) sequence.
2- Add a “G” to 5’ end of target sequence, to obtain a G+(N)19 sequence. Initial “G” is 
important for transcription start by PolIII.
3- Append “GTTTAAGAGCTATGCTGGAAACAG” to the 3’ end of the G+N(19) sequence. This 
is now the forward primer used to amplify the sgRNA scaffold part of the cassette
4- Copy reverse complement of G+N(19), append 
to the 3’ end of this now. This is the reverse primer to amplify the U6 promoter part of the 
cassette
5- Set up the following PCR reaction.Template plasmids are available from Addgene 
(https://www.addgene.org/Lionel_Christiaen/):
6- Check 2 μl of the PCR reaction on a gel. There should be a strong band at ~1.2 kbp. If the 
band is only 1 kbp, the fusion did not occur. In our hands, the success rate is 94%.
Cloning OSO-PCR cassette using In-Fusion
Although OSO-PCR cassettes can be directly tested in Ciona by co-electroporation with 
Cas9 expression plasmid, they can also be processed for cloning into an empty plasmid 
vector. This allows for their replication and long-term propagation in E. coli cells, and 
preparation of pure, highly concentrated sgRNA expression vector plasmid DNA for 
electroporations. We recommend using the In-Fusion restriction enzyme-free cloning system 
from Clontech/Takara (https://www.clontech.com/), though restriction enzyme cloning and 
other systems can be used as well.
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Step-by-step procol:
1- Set up a “Boost” PCR reaction to add 15-nt overhangs to the ends of the cassette required 
for cloning into the empty vector:
2- Add 2 μl DpnI enzyme to the reaction and incubate for 2 hours at 37°C. This will digest 
any remaining template plasmid.
3- Gel-purify boost PCR band, elute in 50 μl water.
4- Set up In-Fusion reaction and incubate at 50°C for 20 minutes:
5- Transform 1 μl in 25 μl of Stellar competent E. coli cells, which come with In-Fusion kit, 
and plate on LB ampicillin agar plate.
6- Pick and grow at least 4 colonies, and screen for positive clones by colony PCR directly 
on cultured E. coli cells using the U6 forward primer (5’- TGGCGGGTGTATTAAACCAC -3’) 
and the In-Fusion reverse primer. The correct band should be ~1 kb in length.
Conventional sgRNA expression vector assembly
sgRNAs expression vectors can also be directly assembled in plasmid form by traditional 
ligation of annealed oligonucleotides into linearized vector. Our initial sgRNA vectors were 
constructed this way and this T4-ligase based method is indeed a faster and more reliable 
approach for obtaining sgRNA expression plasmids. The obvious downside is that colony 
selection and plasmid preparation must be performed before testing sgRNA efficacy, which 
is notoriously difficult to predict a priori. As a result, we do not recommend the following 
method to assemble untested sgRNAs. However, this is a suitable approach to recreate 
expression vectors for sgRNAs that have already been tested and validated.
Step-by-step protocol (adapted from Stolfi et al. 2014):
1- Given the same N(19) + PAM (“NGG”) target sequence that was provided as an example 
for OSO-PCR design:
2- Add a “G” to 5’ end of target sequence, to obtain a G+(N)19 sequence.
Gandhi et al. Page 6
Adv Exp Med Biol. Author manuscript; available in PMC 2018 July 26.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
3- Append  to the 5’ end of the G+N(19) sequence. This is now the sense 
oligonucleotide to be ordered:
4- Copy reverse complement of G+N(19), append  to the 5’ end of this now. This is 
the antisense oligonucleotide:
5- Anneal the oligonucleotides at 10 μM by boiling for 5 minutes in 10 mM Tris pH 7.5, 50 
mM NaCl and then cooling naturally to room temperature.
6- Dilute the annealed oligos 1:1000 and ligate this into U6>sgRNA(F+E) linearized with 
BsaI:
7- Transform this ligation into E. coli cells, and screen colonies by PCR using U6 forward 
primer and the antisense oligonucleotide detailed above as a reverse primer.
Assaying CRISPR knockouts
Either in plasmid or unpurified, PCR product format, sgRNA expression constructs should 
be assayed for their ability to cause on-target CRISPR knockouts. We have encountered a 
wide range of mutagenesis efficacies, from 0% to >60%, estimated by next-generation 
sequencing (GANDHI et al. 2016). Thus, it is advised that one test 4 to 8 candidate sgRNAs 
per target in order to identify the most effective ones to use in further experiments.
It is not absolutely necessary to use an sgRNA expression plasmid to assay its efficacy. We 
have verified highly active sgRNAs expressed from unpurified OSO-PCR products 
electroporated into Ciona embryos. This has allowed us to quickly test the efficacies of large 
numbers of sgRNAs, either by target sequence analysis or by phenotypic assay (GANDHI et al. 
2016). Typically, 15 to 45 µl of unpurified products can be added to a single 700 µl 
electroporation solution, together with the Cas9 vector. However, the linear nature of the 
PCR product, and the reagents present in the reaction may interfere with normal 
development. Therefore, our current strategy is to assay sgRNA efficacy using OSO-PCR 
Gandhi et al. Page 7
Adv Exp Med Biol. Author manuscript; available in PMC 2018 July 26.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
products, but then clone those products that prove most effective into a plasmid for use for 
publication-quality experiments.
There are different methods to estimate sgRNA efficacies in a quantitative manner. A very 
basic approach consists of amplifying target regions by PCR and cloning these products into 
a plasmid vector, then sequencing a handful of clones and counting the number of mutant 
clones (SASAKI et al. 2014; STOLFI et al. 2014). However, this approach is very time 
consuming, labor-intensive, and not accurate since a very large number of clones would need 
to be sequenced to approach a reliable sample size.
sgRNA efficacies have also been measured in Ciona by Cel-I nuclease assay (SASAKI et al. 
2014) or Thermo Fisher Scientific GeneArt Genomic Cleavage Detection kit (STOLFI et al. 
2014). These methods depend on nucleases that recognize and cleave DNA bulges resulting 
from hybridization of DNA strands bearing distinct indels. The result is smaller “cleavage 
bands” that can be measured by fluorescence intensity on an agarose gel. However, the 
nuclease will also cleave bulges resulting from single-nucleotide mismatches, which is 
extremely problematic when using this assay on animals from a highly polymorphic 
population, as we do for Ciona.
More recently, we have employed next-generation sequencing to calculate the ratio of 
mutant and wild-type sequences amplified by PCR (GANDHI et al. 2016). This approach 
allowed us to assay the efficacies of over 80 sgRNAs in parallel, by pooling PCR products 
amplified from embryos electroporated with different sgRNA vectors. However, the cost and 
depth of this method of sequencing would not be justified if you were only measuring a 
handful sgRNAs at a time. Therefore, we only recommend the next-generation sequencing 
route for large-scale assays (>100 sgRNAs).
Sanger sequencing-based “peakshift” assay for sgRNA activity
Currently, our recommended approach for estimating the efficacies of a few sgRNAs at a 
time is to use Sanger sequencing of target sequence PCR products. This is a relatively 
simple and cost-effective method that returns highly consistent, fairly quantitative estimates 
of sgRNA efficacy. Unlike next-generation sequencing, Sanger sequencing cannot resolve 
the sequences of individual molecules, but rather returns a composite of all the molecules 
sequenced in the reaction. Normally, the sequence is readable because all the molecules are 
identical. However, when you have many products bearing short indels due to CRISPR, the 
peaks in a typical Sanger sequencing trace will appear mixed, with signal for more than one 
nucleotide base at the same position in the sequence (Figure 1). This “peakshift” can be 
quantified by algorithms such as the ab1 Peak Reporter by Thermo Fisher Scientific (https://
apps.thermofisher.com/ab1peakreporter/) (ROY AND SCHREIBER 2014). We have shown a nearly 
linear correlation between CRISPR knockout peakshifts measured by ab1 Peak Reporter and 
frequency of a loss-of-function phenotype in F0 (GANDHI et al. 2016). This suggests that the 
sgRNAs that produce the highest peakshifts are the most effective at generating loss-of-
function alleles, which is ultimately the goal of CRISPR knockout experiments.
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Up to three sgRNA cassettes targeting different genes have been electroporated in the same 
embryos and assayed in this manner, and their efficacies do not seem to be hampered by this 
multiplexing (A.S., unpublished observation). However, one must pay attention not to test 
targets that are on the same chromosome, since large deletions or chromosomal breaks may 
occur as a result. What follows is a protocol for electroporating a given sgRNA construct 
(plasmid or OSO-PCR) and assaying its mutagenesis efficacy by peakshift.
Step-by-step protocol (adapted from Gandhi et al. 2016):
1- Following the standard electroporation protocol (CHRISTIAEN et al. 2009), prepare an 
electroporation mix:
This solution is then mixed with 200 μl sea water containing fertilized Ciona eggs for 
electroporation.
2- Grow embryos at 18–24°C until hatching. Collect hatched larvae and extract genomic 
DNA using the QIAamp DNA Micro Kit (Qiagen) following a modified protocol.
Modifications to manufacturer’s protocol:
a. Lyse embryos in 180 μl Buffer ATL + 5 μl proteinase K for 30 minutes
b. Use carrier RNA (as supplied by kit)
c. Elute DNA in 20 μl water
3- Measure the extracted DNA using a spectrophotometer. Prepare the following PCR 
reaction to amplify the target sequence. For best results, you should aim to design primers to 
amplify a fragment 300–1500 bp long, with the target site(s) at least 150 bp away from 
either end of the fragment. We prefer Pfx platinum from Thermo Fisher Scientific, but any 
proof-reading polymerase should suffice.
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4- Column- or gel-purify the resulting PCR product, and send off for Sanger sequencing. 
The primers used for sequencing can be the same used for PCR, provided the target is at 
least 150 bp and at most 500 bp away from the primer. This ensures large enough stretches 
of “normal” and “shifted” peaks for a proper quantification by ab1 Peak Reporter. The 
orientation of sequencing does not matter, but it is critically important to avoid sequencing 
reads that may encounter naturally occurring indels before the target site, which can cause a 
natural peakshift and mask the effect of CRISPR. You may have to design and test several 
internal primers specifically for sequencing, if the PCR primers are not suitable.
5- The resulting .ab1 sequencing file are then uploaded to Thermo Fisher Scientific’s ab1 
Peak Reporter (https://apps.thermofisher.com/ab1peakreporter/), which may require 
registering/logging in to the Thermo Fisher website. The program will return a .csv file, 
which can be opened in Microsoft Excel and saved as an .xlsx file.
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6- The data should first be filtered as to only display the values at each peak called. This is 
because the data contain signal reads at every position measured by the instrument, 
including in between peaks (in between individual basepairs in the sequence). To do this, 
create a filter for the “BaseCall” column (column B) and exclude “-”. You will be left with 
only the peaks, represented by “calls” indicating G, A, T, C, or N.
7- After filtering this way, you can now search for your target sequence and PAM in column 
B, displayed as 5’ to 3’ from top to bottom (Figure 2). Once you have found your target 
sequence, color-coding it may help you keep track of your position in the file.
8- In column U, calculate the sum of the secondary peaks by adding the values in columns 
H-K (“MaxSig7Scan Filtered Ratios”) and subtracting 1. Subtracting 1 is to remove the 
contribution of the primary peak, which is always 1 regardless of its actual identity.
9- To get a quantitative estimate of the peakshift resulting from mutant reads, calculate the 
average value in column U, over 30 positions donwstream of (3’ to) the Cas9 cleavage site, 
usually around the 3rd basepair in the target from the PAM. To get a sense of the secondary 
signal background of your read, calculate the average in column U over 30 positions 
upstream of the cleavage site. Subtracting this background average from the peakshift 
average, you can obtain a corrected peakshift value.
Bear in mind that the peakshift can be suppressed by sequence homogeneity near the target 
site. Because CRISPR knockouts are usually short indels, shifting peaks of the same identity 
will not be detected. For instance, a 1-bp deletion in the sequence GGGGAAAA will only 
produce secondary peaks at one position, while a 1-bp deletion in the sequence GAGAGAGA 
will result in secondary peaks at all positions.
Conclusion
As more Ciona research groups adopt CRISPR, more data will emerge on the best practices 
to ensure optimal CRISPR activity, including sgRNA efficacy prediction. We hope the above 
protocols will speed up this adoption and bring about exciting improvements to CRISPR 
knockout strategies in Ciona.
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Fig.1. CRISPR indels
a) Wild-type (“wt”) target sequence aligned with two CRISPR knockout mutant sequences 
(“m1” and “m2”) generated by imprecise repair of CRISPR/Cas9-mediated double-stranded 
breaks. Alignment shows gaps (−) in place of missing nucleotides in target or PAM 
sequence. b) When sequenced by Sanger sequencing, pools of wild-type and mutant 
sequences will produce a “peakshift”, which can be quantified by ab1 Peak Reporter web 
app (see text for details). Below, the same sequences in (a) aligned without gaps, showing 
the cause of the overlapping peaks seen in the peakshift area. Asterisks denote naturally-
occurring single-nucleotide polymorphisms.
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Fig.2. ab1 Peak Reporter spreadsheet
Annotated example of an excel spreadsheet generated by the ab1 Peak Reporter web app. 
Each row represents a called peak, or nucleotide, of the sequence, from 5’ to 3’ (top to 
bottom, respectively). Cells of interest color coded or outlined manually. In yellow, the 
sgRNA target and in red, the PAM. In light blue, the MaxSig7Scan ratios for 30 nucleotides 
upstream of the Cas9 cut site, and in pink, the MaxSig7Scan ratios of 30 nucleotides 
downstream of the Cas9 cut site. Cas9 tend to cut in the target, ~3 basepairs from the PAM. 
Outlined in red box: the sum of secondary MaxSig7Scan ratios for each nucleotide, using 
the formula indicated. The average of these values after the Cas9 cut site represents the 
“peakshift”, the amount of secondary peak calling due to presence of sequences with short 
indels in the target. The average of the value before the Cas9 cut site is the background 
signal. See text for details.
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